Voyager Therapeutics, Inc.

VYGR

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001640266

D/E

on the D/E boundary of 370 graded peers in healthcare

rank 295 of 370; percentile 79.7; sampling error 2.5 points; lower is stronger

A B C D E

D/E, the sloth



Scoreboard	
Profitability	E percentile 86.6
Solvency	B/C percentile 42.4
Growth and financing	C percentile 48.2
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $252.3M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 9, 2026 227 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$2.02 2026-10-21; market equity $124.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 9, 2026

We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 86.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	4.0%	(6.6%)		86.6	809	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 42.4					
Twelve-month failure probability	0.11%	0.07%	61.8	247	2026-06-30
Altman Z double-prime	(1.03)	(0.33)	41.4	754	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31					
Current ratio	7.64x	2.94x	23.9	837	2025-12-31
Growth and financing, sleeve percentile 48.2					
Revenue growth, three-year compound	(0.4%)	10.1%	71.8	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	16.5%	2.1%	24.5	703	2025-12-31
Net share issuance, one year	8.0%	2.5%	48.3	634	2026-03-02

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.6 months

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
290	Gilead Sciences, Inc. (GILD)	78.3	D/E	
291	Whitehawk Therapeutics, Inc. (WHWK)	78.6	D/E	
292	Ironwood Pharmaceuticals Inc. (IRWD)	78.9	D/E	late filer, fortress balance sheet
293	X4 Pharmaceuticals, Inc. (XFOR)	79.1	D/E	dilution, fortress balance sheet
294	Champions Oncology, Inc. (CSBR)	79.4	D/E	
295	Voyager Therapeutics, Inc. (VYGR)	79.7	D/E	short runway
296	Lucid Diagnostics Inc. (LUCD)	79.9	D/E	dilution
297	Personalis, Inc. (PSNL)	80.2	D/E	
298	Lexicon Pharmaceuticals, Inc. (LXRX)	80.5	D/E	fortress balance sheet
299	Merck & Co., Inc. (MRK)	80.8	D/E	
300	C4 Therapeutics, Inc. (CCCC)	81.0	D/E	dilution, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-21 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(26.1%)	7.7%	27
Distance from 52-week high	(59.6%)	(30.1%)	18
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	(108.5%)	(1.0%)	6
Book value to price	1.24	0.28	91
Sales to price	0.32	0.31	52
Composite equity issuance, five years	49.3%	20.5%	65
Relative strength against the sector, log excess return	(0.51)	(0.14)	27

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$35.8M
Operating cash flow, four quarters	-$120.6M
Months of runway	3.6
Days since last periodic filing	77 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$1.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$119.7M	2025-12-31	2026-03-09	10-K	26-025197
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$132.5M	2025-12-31	2026-03-09	10-K	26-025197
3	assets	us-gaap:Assets	$252.3M	2025-12-31	2026-03-09	10-K	26-025197
4	assets	us-gaap:Assets	$393.1M	2024-12-31	2026-03-09	10-K	26-025197
5	current assets	us-gaap:AssetsCurrent	$202.7M	2025-12-31	2026-03-09	10-K	26-025197
6	current liabilities	us-gaap:LiabilitiesCurrent	$26.5M	2025-12-31	2026-03-09	10-K	26-025197
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$445.9M	2025-12-31	2026-03-09	10-K	26-025197
8	operating income	us-gaap:OperatingIncomeLoss	-$131.8M	2025-12-31	2026-03-09	10-K	26-025197
9	book equity	us-gaap:StockholdersEquity	$196.1M	2025-12-31	2026-03-09	10-K	26-025197
10	liabilities	us-gaap:Liabilities	$56.2M	2025-12-31	2026-03-09	10-K	26-025197
11	operating income	us-gaap:OperatingIncomeLoss	-$20.3M	2015-12-31	2018-03-14	10-K	18-002038
12	interest expense	us-gaap:InterestAndDebtExpense	$9.4M	2015-12-31	2016-03-17	10-K	16-004222
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.4M	2025-12-31	2026-03-09	10-K	26-025197
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$80.0M	2024-12-31	2026-03-09	10-K	26-025197
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$250.0M	2023-12-31	2026-03-09	10-K	26-025197
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.9M	2022-12-31	2025-03-11	10-K	25-002703
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.6M	2025-12-31	2026-03-09	10-K	26-025197
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$15.3M	2024-12-31	2026-03-09	10-K	26-025197

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.5M	2024-12-31	2026-03-09	10-K	26-025197
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$77.9M	2023-12-31	2026-03-09	10-K	26-025197
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.3M	2023-12-31	2026-03-09	10-K	26-025197
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.5M	2022-12-31	2025-03-11	10-K	25-002703
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2022-12-31	2025-03-11	10-K	25-002703
24	depreciation amortization	us-gaap:Depreciation	$4.1M	2025-12-31	2026-03-09	10-K	26-025197
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$119.6M	2025-12-31	2026-03-09	10-K	26-025197
26	income tax	us-gaap:IncomeTaxExpenseBenefit	$144,000	2025-12-31	2026-03-09	10-K	26-025197
27	current assets	us-gaap:AssetsCurrent	$276.8M	2024-12-31	2026-03-09	10-K	26-025197
28	current liabilities	us-gaap:LiabilitiesCurrent	$49.8M	2024-12-31	2026-03-09	10-K	26-025197
29	assets	us-gaap:Assets	$351.3M	2023-12-31	2025-03-11	10-K	25-002703
30	assets	us-gaap:Assets	$159.4M	2022-12-31	2024-02-28	10-K	24-001988
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	59,599,375	2026-03-02	2026-03-09	10-K	26-025197
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	55,206,885	2025-03-03	2025-03-11	10-K	25-002703

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.